Why Methotrexate Is Still the Anchor Drug in Rheumatoid Arthritis

Methotrexate is still the first-line anchor for rheumatoid arthritis because the 2021 American College of Rheumatology (ACR) guideline judges every option against efficacy, long-term safety, durability, and cost under a formal grading system, and methotrexate keeps clearing that bar. A patient reading the guideline well is really doing two things at once: seeing what it recommends, and seeing how sure it is about each recommendation. Those are separate questions, and the second one is where most misunderstandings begin.

Key points#

• The guideline strongly recommends starting methotrexate alone for most people beginning treatment, ahead of other conventional pills and ahead of biologics.
• It strongly recommends a treat-to-target approach: pick a goal, measure it, and adjust when it is not met.
• It strongly recommends against routine longer-term steroids, defined as three months or more.
• A "strong" label does not mean the evidence is airtight. Strength of recommendation and certainty of evidence are two different dials.

Two dials, not one#

Every recommendation in a modern guideline sits on two independent dials, and confusing them is the most common reading error.

The first dial is certainty: how good is the underlying evidence, rated from high down to very low. The second dial is strength: how firmly the panel points you toward a given action. A strong recommendation means the experts expect nearly everyone with the full picture to make the same choice. A conditional recommendation means the right answer honestly depends on the individual, so preferences, other conditions, and cost should carry the decision.

Here is the part that surprises people. A strong recommendation does not require strong evidence. Several of the guideline's firmest calls rest on low or very low certainty, because the panel decided that benefits, harms, cost, and practicality all pointed the same way even when the trial data were thin. Holding those two dials apart is the single skill that makes the rest of the document readable.

The 2021 guideline, authored by Fraenkel and colleagues, carries 44 recommendations. Only seven are strong; the remaining 37 are conditional. That lopsided ratio is not timidity. It is an honest map of where the evidence is settled and where it is not.

Why methotrexate keeps winning the comparison#

For someone who has never taken a disease-modifying antirheumatic drug (DMARD) and has moderate-to-high disease activity, the guideline strongly recommends methotrexate on its own over hydroxychloroquine or sulfasalazine, and strongly recommends methotrexate on its own over starting a biologic or a targeted synthetic DMARD.

That second point is the one that raises eyebrows, so it is worth stating the panel's reasoning plainly. Newer biologic and targeted drugs work well; no one argues otherwise. The panel's judgment was that methotrexate delivers comparable early benefit for most people while carrying decades of safety experience and a fraction of the cost, and that leading with a biologic offers no reliable edge big enough to justify going first. Safety questions circling one class of targeted synthetic drugs, the JAK inhibitors, which were under active regulatory review as the guideline was finished, sharpened that comparison further.

Methotrexate also stays central when the first attempt underdelivers. The guideline conditionally prefers methotrexate alone over dual or triple conventional-DMARD combinations, and over methotrexate plus a tumor necrosis factor inhibitor, as the opening move for many people. And when someone is not at target on oral methotrexate, the panel conditionally favors getting more out of methotrexate itself, by switching to the subcutaneous injectable form or splitting the dose, before adding or swapping in a different drug. The rationale is stated openly: even with very low certainty for those tactics, methotrexate's mix of benefit, long-term safety, and low cost makes it the thing to maximize first.

That is what "anchor" means in practice. Methotrexate is not a placeholder to hurry past. It is the fixed reference point the other decisions orbit.

The target matters more than the first drug#

The sturdiest structural idea in the whole guideline is not any single medication. It is treat-to-target. For people not previously treated with biologic or targeted synthetic DMARDs, a treat-to-target approach is strongly recommended over usual care. In plain terms, the clinician sets a defined goal of remission or low disease activity, measures it on a regular schedule, and changes the plan when the goal is missed.

Worth noticing: that strong recommendation rests on low-certainty evidence, one more reminder that the two dials move on their own. Treat-to-target is also what makes a methotrexate-first plan safe rather than stubborn. If methotrexate is fully optimized and the target still is not reached, the framework is built to escalate on purpose, not to cling to the anchor out of habit.

The steroid question#

Steroids are where the guideline draws its hardest line on harm. It strongly recommends starting a conventional synthetic DMARD without longer-term glucocorticoids, defined as three months or more, rather than with them. It also conditionally advises against even short courses, while frankly acknowledging that brief steroid bursts are often needed in real life to settle symptoms until a DMARD takes hold. For someone leaning on steroids to stay at target, the guideline conditionally prefers adjusting or adding DMARDs over continuing the steroid.

The driving concern is cumulative-dose harm. Glucocorticoids act fast, but sustained use carries genuine risks including infection, bone loss, and cardiovascular effects. Read closely, this section treats steroids as a bridge to cross and leave behind, not a floor to stand on. It also differs somewhat from some other international recommendations, a useful reminder that thoughtful panels can weigh the same evidence and land in different places.

Where the guideline leaves room for you#

Assembled, the document offers a simple mental model. Where it speaks strongly, as with treat-to-target and methotrexate-first, it is naming a default that fits most people. Where it speaks conditionally, which is most of the 44 recommendations, it is inviting a real conversation about your priorities, your other health conditions, and cost. The methotrexate anchor holds for a concrete reason: under formal grading it keeps clearing the bar of proven benefit against acceptable risk, which is a firmer footing than age or price alone.